Alnylam Pharmaceuticals Inc (ALNY)vsUroGen Pharma Ltd (URGN)
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
URGN
UroGen Pharma Ltd
$18.12
+2.60%
HEALTHCARE · Cap: $882.12M
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 3283% more annual revenue ($3.71B vs $109.79M). ALNY leads profitability with a 8.5% profit margin vs -139.8%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
ALNY
Hold49
out of 100
Grade: D+
URGN
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Intrinsic value data unavailable for URGN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Revenue surging 54.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1481.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bull Case : URGN
The strongest argument for URGN centers on Revenue Growth, Debt/Equity. Revenue growth of 54.0% demonstrates continued momentum.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Bear Case : URGN
The primary concerns for URGN are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
URGN carries more volatility with a beta of 1.37 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ALNY scores higher overall (49/100 vs 28/100) and 84.9% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
UroGen Pharma Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
UroGen Pharma Ltd (URGN) is a biotechnology company focused on pioneering therapies for urological conditions, particularly urothelial carcinoma and bladder cancer. Utilizing its proprietary reverse thermal gel platform, UroGen facilitates sustained local drug delivery, enhancing therapeutic effectiveness while minimizing systemic exposure. The company boasts a robust clinical pipeline aimed at addressing critical unmet needs within urology, positioning itself as a leader in the sector with the potential to significantly improve patient outcomes.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?